Q32 Bio (QTTB) Guggenheim’s Inaugural Healthcare Innovation Conference summary

Key assets and upcoming catalysts

• Two main focus areas: complement therapeutics/tissue targeting and immune modulation.

• Lead compound 097 in complement therapeutics has readouts expected next year.

• Bempikibart, an in-licensed asset, is nearing phase 2a readouts in atopic dermatitis and alopecia areata, expected in December.

• Additional assets and research candidates are in the pipeline.

• Company is focused on both innate and adaptive immunity.

Bempikibart mechanism and differentiation

• Bempikibart is a bifunctional antibody targeting IL-7 receptor alpha, inhibiting both TSLP and IL-7 pathways.

• Enables broad modulation of both TH2 and TH1 immune responses.

• Differentiated from TSLP-only antagonists by also modulating T cell responses via IL-7.

• Offers potential advantages over previous approaches that targeted only TSLP.

Clinical trial design and patient population

• Atopic dermatitis trial is a monotherapy study in moderate to severe patients, allowing prior biologic exposure.

• Baseline EASI scores expected in the low to mid 20s, consistent with contemporary trials.

• Alopecia areata trial targets severe and very severe patients, with endpoints focused on SALT 20.

• Both studies are designed to align with current standards and comparators in their respective indications.